Vutrisiran for Transthyretin Amyloidosis Cardiomyopathy.
作者信息
Lehker Angelica, Mukherjee Debabrata
机构信息
Department of Internal Medicine, Texas Tech University Health Sciences Center at El Paso, El Paso, Texas, USA.
出版信息
Curr Vasc Pharmacol. 2025;23(4):225-227. doi: 10.2174/0115701611385466250411100340.
Abstract
摘要
相似文献
1
Vutrisiran for Transthyretin Amyloidosis Cardiomyopathy.
Curr Vasc Pharmacol. 2025;23(4):225-227. doi: 10.2174/0115701611385466250411100340.
2
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B.
J Am Coll Cardiol. 2025 Aug 12;86(6):459-475. doi: 10.1016/j.jacc.2025.04.055.
3
Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy.
J Am Coll Cardiol. 2025 Aug 12;86(6):444-455. doi: 10.1016/j.jacc.2025.06.022.
4
Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial.
J Am Coll Cardiol. 2025 Feb 25;85(7):753-761. doi: 10.1016/j.jacc.2024.11.015. Epub 2024 Nov 18.
5
Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy.
J Am Coll Cardiol. 2025 May 27;85(20):1927-1939. doi: 10.1016/j.jacc.2025.03.477. Epub 2025 Mar 17.
6
Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy.
J Am Coll Cardiol. 2025 May 27;85(20):1943-1955. doi: 10.1016/j.jacc.2025.03.454. Epub 2025 Mar 17.
7
Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B.
J Am Coll Cardiol. 2025 Apr 30. doi: 10.1016/j.jacc.2025.04.008.
8
Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary.
Future Cardiol. 2025 Jun;21(8):555-565. doi: 10.1080/14796678.2025.2493019. Epub 2025 May 15.
9
Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B.
JACC Adv. 2025 Aug 22;4(9):102066. doi: 10.1016/j.jacadv.2025.102066.
10
Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Eur J Heart Fail. 2024 Feb;26(2):397-410. doi: 10.1002/ejhf.3138. Epub 2024 Feb 6.
Zotero 插件